Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis
- PMID: 20460524
- DOI: 10.1158/0008-5472.CAN-09-4479
Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis
Abstract
Members of the fibroblast growth factor receptor (FGFR) family have essential roles in normal physiology and in cancer where they control diverse processes. FGFRs have been associated with breast cancer development. Thus, models to study the role of FGFR in breast cancer and their targeting potential are important. We present an in vitro and in vivo analysis of FGFRs in the breast cancer model cell lines 67NR and 4T1. We show that both tumor cell lines coexpress FGFRs and ligands and display autocrine FGFR signaling activity. Fibroblast growth factor receptor substrate 2 (FRS2), a downstream mediator of FGFR, is constitutively tyrosine phosphorylated and multiple signaling pathways are active. Treatment of 67NR and 4T1 cultures with TKI258, an FGFR tyrosine kinase inhibitor (TKI), caused a rapid decrease in FRS2 phosphorylation; decreased the activity of extracellular signal-regulated kinase 1/2 (ERK1/2), AKT, and phospholipase Cgamma; and blocked proliferation of both tumor lines. Furthermore, TKI258 induced 4T1 apoptotic cell death via blockade of the phosphoinositide 3-kinase/AKT pathway. In vivo, one dose of TKI258 rapidly lowered FRS2 phosphorylation and ERK1/2 and AKT activity in mammary tumors. Long-term TKI258 treatment of 4T1 tumor- and 67NR tumor-bearing mice had a significant effect on primary tumor outgrowth and 4T1 tumor-induced lung metastases. A microarray analysis was carried out to identify targets with roles in TKI258 antitumor activity and potential prognostic markers in human breast tumors. Of interest are the downregulated matrix metalloproteases (MMP), in particular MMP9, which is essential for metastatic spread of 4T1 tumors.
(c)2010 AACR.
Similar articles
-
The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression.Cancer Res. 2009 Jul 15;69(14):5690-8. doi: 10.1158/0008-5472.CAN-08-4573. Epub 2009 Jul 7. Cancer Res. 2009. PMID: 19584287
-
Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.Clin Cancer Res. 2005 Apr 1;11(7):2702-12. doi: 10.1158/1078-0432.CCR-04-2057. Clin Cancer Res. 2005. PMID: 15814652
-
Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.Oncogene. 2004 Jul 1;23(30):5161-74. doi: 10.1038/sj.onc.1207659. Oncogene. 2004. PMID: 15122317
-
Anticancer molecules targeting fibroblast growth factor receptors.Trends Pharmacol Sci. 2012 Oct;33(10):531-41. doi: 10.1016/j.tips.2012.07.001. Epub 2012 Aug 9. Trends Pharmacol Sci. 2012. PMID: 22884522 Review.
-
Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers.Z Gastroenterol. 2005 Oct;43(10):1133-9. doi: 10.1055/s-2005-858638. Z Gastroenterol. 2005. PMID: 16220453 Review.
Cited by
-
Fibronectin induces endothelial cell migration through β1 integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653/654 and 766.J Biol Chem. 2012 Mar 2;287(10):7190-202. doi: 10.1074/jbc.M111.304972. Epub 2012 Jan 14. J Biol Chem. 2012. PMID: 22247553 Free PMC article.
-
Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer.Mol Cancer Ther. 2016 Sep;15(9):2096-106. doi: 10.1158/1535-7163.MCT-16-0136. Epub 2016 Jul 1. Mol Cancer Ther. 2016. PMID: 27371729 Free PMC article.
-
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.Breast Cancer Res Treat. 2015 Feb;150(1):1-8. doi: 10.1007/s10549-015-3301-y. Epub 2015 Feb 13. Breast Cancer Res Treat. 2015. PMID: 25677745 Free PMC article. Review.
-
The mutational landscape of adenoid cystic carcinoma.Nat Genet. 2013 Jul;45(7):791-8. doi: 10.1038/ng.2643. Epub 2013 May 19. Nat Genet. 2013. PMID: 23685749 Free PMC article.
-
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.Invest New Drugs. 2013 Apr;31(2):265-72. doi: 10.1007/s10637-012-9851-5. Epub 2012 Jul 17. Invest New Drugs. 2013. PMID: 22801803
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous